Molecular markers in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer

Abstract

The invention discloses a molecular marker used in the early diagnosis of non-small cell lung cancer in peripheral blood mononuclear cells. The invention provides a substance for detecting the expression level of the CD226 gene in the PBMC of a subject, a substance for detecting the expression level of the CD247 gene in the PBMC of the subject, and a substance for detecting the amount of smoking of the subject. 1) and / or 2) applications in products with functions: 1) detecting or assisting in detecting whether a subject has non-small cell lung cancer; 2) distinguishing or assisting in distinguishing whether a subject is non-small cell lung cancer or benign lung nodules Patient; the smoking amount is whether the annual smoking amount is greater than 40 packs. Experiments of the present invention have proved that the diagnostic combination composed of CD226, CD247 and the patient's smoking amount (greater than 40 packs / year) can effectively distinguish non-small cell lung cancer patients from benign nodules in the lungs, and is expected to become the first choice for early diagnosis of non-small cell lung cancer. molecular markers.

Description

technical field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a molecular marker in peripheral blood mononuclear cells for early diagnosis of non-small cell lung cancer. Background technique

[0002] The 2018 global cancer statistics show that lung cancer is still the first malignant tumor in terms of incidence (11.6%) and mortality (18.4%). Due to the accelerated process of industrial development, the aggravation of air pollution and the increase in the number of smokers, the incidence and mortality of lung cancer are increasing year by year, and the situation is very serious. Nearly 85% of all lung cancer cases are non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC), mainly including squamous cell carcinoma, adenocarcinoma, large cell carcinoma and so on. Non-small cell lung cancer has a high degree of malignancy, a low 5-year survival rate, and 70% of patients have advanced lung cancer when they were first diagnosed. ...

Images